Diagnosis and treatment of high blood pressure : internationals standards and divergences
Diagnosis and treatment of high blood pressure: internationals standards and divergences. High blood pressure affects more than 1.4 billion people worldwide and this number is increasing. Three international recommendations were published between 2017 and 2018. Essential hypertension is defined differently from one recommendation to another; AHA/ACC recommendations retain 130/80 mmHg, compared to 140/90 mmHg for Canada and Europe, resulting in a higher prevalence of hypertension. The management of hypertensive patients is based on 2 axes: a non-pharmacological axis that must be recalled at each consultation, and a pharmacological axis; for which the American and European guidelines recommend the introduction of a dual therapy, pharmacologically complementary, when initiating treatment in hypertensive patients. Blood pressure targets are lower in the United States than in Canada and Europe.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
La Revue du praticien - 69(2019), 10 vom: 12. Dez., Seite 1083-1086 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Diagnostic et traitement de l’hypertension artérielle : normes et divergences internationales |
|---|
| Beteiligte Personen: |
Fayol, Antoine [VerfasserIn] |
|---|
| Themen: |
Antihypertensive Agents |
|---|
| Anmerkungen: |
Date Completed 01.05.2020 Date Revised 01.05.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM308230876 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308230876 | ||
| 003 | DE-627 | ||
| 005 | 20231225131309.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1027.xml |
| 035 | |a (DE-627)NLM308230876 | ||
| 035 | |a (NLM)32237577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Fayol, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and treatment of high blood pressure |b internationals standards and divergences |
| 246 | 3 | 3 | |a Diagnostic et traitement de l’hypertension artérielle : normes et divergences internationales |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.05.2020 | ||
| 500 | |a Date Revised 01.05.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Diagnosis and treatment of high blood pressure: internationals standards and divergences. High blood pressure affects more than 1.4 billion people worldwide and this number is increasing. Three international recommendations were published between 2017 and 2018. Essential hypertension is defined differently from one recommendation to another; AHA/ACC recommendations retain 130/80 mmHg, compared to 140/90 mmHg for Canada and Europe, resulting in a higher prevalence of hypertension. The management of hypertensive patients is based on 2 axes: a non-pharmacological axis that must be recalled at each consultation, and a pharmacological axis; for which the American and European guidelines recommend the introduction of a dual therapy, pharmacologically complementary, when initiating treatment in hypertensive patients. Blood pressure targets are lower in the United States than in Canada and Europe | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a guidelines | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 700 | 1 | |a Boutouyrie, Pierre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue du praticien |d 1951 |g 69(2019), 10 vom: 12. Dez., Seite 1083-1086 |w (DE-627)NLM000023248 |x 2101-017X |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2019 |g number:10 |g day:12 |g month:12 |g pages:1083-1086 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2019 |e 10 |b 12 |c 12 |h 1083-1086 | ||